The FDA has provided communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil—indicated for colorectal, breast, gastric/esophageal/gastroesophageal, and pancreatic cancers—related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency.
Using data from the STS General Thoracic Surgery Database—the largest clinical thoracic surgical database in North America, with nearly 800,000 procedure records and more than 900 participating surgeons—researchers found that more cancers were identified in N1 than N2 nodes, with many located in N1 nodes adjacent to the bronchi.
“Our results support the need for continued studies of acral melanoma as a distinct entity from cutaneous melanoma. We should also consider additional investigations of Agent Orange as a risk factor for acral melanoma and evaluate whether a similar link might exist with other herbicides.”
|
_2828287.jpg)
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s, two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding Director of the Colon and Rectal Cancer Center at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School, and her colleagues, find other alarming trends in early-onset gastrointestinal cancers.
